[Prospects of using controlled-action lactoglobulins in the treatment of acute intestinal infections and dysbacteriosis in infants].
The author summarizes the results of the preclinical study and clinical trial of the new biological drug lactoglobulin having an +anti-coli-proteus action. Shows that the drug holds promise in the treatment of infants with acute intestinal infections and dysbacteriosis as well as in the enrichment of lactic mixtures used for artificial feeding of premature children and babies referred to the risk group.